The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: Results from the ELDERLY MANTLE‐FIRST study
Year: 2025
Type: article
Abstract: Mantle cell lymphoma (MCL) is an aggressive and incurable disease.1,2 Most patients are over 65 years old and exhibit heterogeneous fitness status alongside multiple comorbidities.Until now, conventional chemo-immunotherapy (CIT) followed by rituximab maintenance has represented the standard approach for elderly patients.3 Approximately 40% of MCL patients experience disease relapse or progression (POD) within 24 months from diagnosis and have been defined as early-POD.4 The MANTLE-FIRST study has divided patients' outcome depending on time to first relapse (early-vs.late-POD) after intensive upfront therapy including high-dose cytarabine.5,6 However, the predictive significance of early-POD in elderly MCL patients following less intensive frontline treatment is not well HemaSphere.
Source: HemaSphere
DOI: 10.1002/hem3.70254
Authors: Francesca Maria Quaglia, Annalisa Arcari, Lucia Morello, Luigi Marcheselli, Alessandra Tucci, Chiara Pagani, Valentina Bozzoli, Greta Scapinello, Francesco Piazza, Vittorio Ruggero Zilioli, Cristina Muzi, Benedetta Puccini, Benedetta Sordi, Maria Chiara Tisi, Nicolò Rampi, Alessia Castellino, Sara Veronica Usai, Jari Paternoster, Emanuele Cencini, Simone Ferrero, Chiara Consoli, Marco Basso, Elisa Lucchini, Elsa Pennese, Maria Elena Nizzoli, Michele Spina, Luca Pezzullo, Maria Stella De Candia, Rita Tavarozzi, Mauro Krampera, Carlo Visco
Institutions: Azienda Ospedaliera Universitaria Integrata Verona, Guglielmo da Saliceto Hospital, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Ospedale Vito Fazzi, University of Padua, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Azienda Ospedaliero-Universitaria Careggi, Ospedale San Bortolo, University of Milan, Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo, Azienda Ospedaliera G. Brotzu, University of Verona, University of Siena, Azienda Ospedaliera Universitaria Senese, University of Turin, Istituto Oncologico Veneto, Azienda sanitaria universitaria Giuliano Isontina, University of Modena and Reggio Emilia, Azienda Sanitaria Unità Locale di Reggio Emilia, Centro di Riferimento Oncologico, AOU San Giovanni di Dio e Ruggi d'Aragona, Istituto Tumori Bari, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,480
OpenAlex ID: W4417112712